INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.2, ss.156-160, 2008 (SCI-Expanded)
Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.